Clinical Trial Update: To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial of belantamab mafodotin in combination with either lenalidomide-dexamethasone or bortezomib-dexamethasone for relapsed/refractory mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-05-20